InGel Therapeutics
PrivateLast Round
Grant
Dec 2, 2024
Total Funding Raised
$13.48M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
InGel Therapeutics is a biotechnology company developing engineered cell therapies designed to target neuroprotective pathways to treat retinal degeneration.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
InGel Therapeutics Comparables
Compare InGel Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Opsis Therapeutics | 86% | |
| jCyte, Inc. | 85% | |
| Nanoscope Therapeutics Inc. | 82% |
InGel Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 2, 2024 | ||||
| Seed | Jul 1, 2024 | ||||
| Grant | May 4, 2023 | ||||
| Accelerator | Sep 1, 2022 |
Key People
Founding team and executive leadership
InGel Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Bertarelli Foundation | Grant |
| ARPA-H | Grant |
| The Venture Collective | Seed |
| Nucleate | Accelerator |
| Harvard President's Innovation Challenge | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 17, 2026
Monthly visitors increased 73% MoM to 2.1K.
- Nov 10, 2025
Monthly visitors grew 51% MoM, from 885 to 1.3K.
InGel Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about InGel Therapeutics's valuation, stock price, and market status.
Is InGel Therapeutics a public or private company?
InGel Therapeutics is a private company.
What is the current stock price of InGel Therapeutics?
InGel Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is InGel Therapeutics worth (valuation)?
Valuation information for InGel Therapeutics is not publicly available.
Can I buy InGel Therapeutics stock?
InGel Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was InGel Therapeutics's last funding round?
Funding round information for InGel Therapeutics is not publicly available.
Who are the main investors in InGel Therapeutics?
Investor information for InGel Therapeutics is not publicly disclosed.
Will InGel Therapeutics IPO soon?
No public IPO plans have been announced for InGel Therapeutics.
How can I track InGel Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor InGel Therapeutics's secondary market activity and sign up for updates.